Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 104

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 104
---
 2024                            |     |     |  11.00 
 (34.38 | ) |
|:--------------------------------------------------------------------------------------------------|:----|:----|-------:|:--|
| Increase in net tangible book value per share attributable to the pro forma adjustments described 
 above                                                                                             |     |     |  34.11 |   |
| Pro forma net tangible book value per share as of ‌ December 31, 2024                             |     |     |  (0.27 | ) |
| Increase in net tangible book value per share attributable to new investors                       |     |     |   1.72 |   |
| Pro forma as adjusted net tangible book value per share after this offering                       |     |     |   1.45 |   |
| Dilution per share to new investors                                                               |     |     |   9.55 |   |
| Percentage of dilution in net tangible book value per share for new investors                     |     |     |     86 | % |

The pro forma and pro
forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price
and other terms of this offering determined at pricing. A $0.25 increase (decrease) in the assumed initial public offering price of $11.00 per
Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our
pro forma as adjusted net tangible book value as of December 31, 2024 after this offering by approximately $0.05 per Ordinary Share,
and would increase (decrease) dilution to investors in this offering by $0.20 per Ordinary Share, assuming that the number of Ordinary
Share offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Ordinary Shares
we are offering. An increase (decrease) of 100,000 in the number of Ordinary Shares we are offering would increase (decrease) our pro
forma as adjusted net tangible book value as of December 31, 2024 after this offering by approximately $0.12 per Ordinary Share,
and would decrease (increase) dilution to investors in this offering by approximately $0.12 per Ordinary Share, assuming the assumed
initial public offering price per